Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
NCT06830590 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-08-13
Summary
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
Conditions
- Breast Cancer
- Molecular Pathway Deregulation
- Treatment
Interventions
- PROCEDURE
-
Molecular characterisation
All patients treated by surgery were included without any neoadjuvant therapy
Sponsors & Collaborators
-
Liaquat University of Medical & Health Sciences
lead OTHER
Principal Investigators
-
Binafsha Manzoor M Syed, MBBS, PhD · Liaquat University of Medical & Health Sciences, Jamshoro
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-01
- Primary Completion
- 2025-12-30
- Completion
- 2025-12-31
Countries
- Pakistan
Study Locations
More Related Trials
-
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
NCT01958021 ·Status: COMPLETED ·Phase: PHASE3
-
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
NCT05190094 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776 ·Status: RECRUITING
-
Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib
NCT01248897 ·Status: COMPLETED
-
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
NCT06338644 ·Status: NOT_YET_RECRUITING
-
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT05489679 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NCT04707196 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT05851014 ·Status: RECRUITING ·Phase: PHASE3
-
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
NCT02679755 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
NCT04937660 ·Status: COMPLETED
-
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
NCT05399329 ·Status: COMPLETED
-
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
NCT05054166 ·Status: COMPLETED
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT02595762 ·Status: COMPLETED
-
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NCT06172322 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
NCT06605690 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
NCT06974929 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
NCT00708903 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
NCT02611310 ·Status: TERMINATED
-
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
NCT04289974 ·Status: UNKNOWN
-
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
NCT05263570 ·Status: RECRUITING
-
A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
NCT05953909 ·Status: UNKNOWN
-
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
NCT02499146 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
NCT05584644 ·Status: COMPLETED